文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

静脉瑞德西韦治疗成人重症COVID-19有效性与安全性的评估:3期随机双盲安慰剂对照多中心试验的研究方案

Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
PubMed 文献 · Trials · 2020-05-24

本研究为3期随机双盲安慰剂对照多中心试验,旨在评估静脉瑞德西韦在成人重症COVID-19患者中的有效性与安全性。受试者为实验室确诊、有重症肺炎表现且影像学确认的成人患者,按2:1随机接受瑞德西韦或安慰剂静脉给药10天。主要终点为临床改善时间(28天内),定义为六分类临床状态量表下降两类或出院。

要点

  • 瑞德西韦组与安慰剂组按2:1随机,静脉给药10天。
  • 主要终点为28天内临床改善时间(六分类量表下降两类或出院)。
  • 计划在观察到所需事件总数一半时进行疗效与无效性中期分析。

核心结论

  • 该方案旨在评估静脉瑞德西韦对成人重症COVID-19的疗效与安全性。

研究设计与样本

  • 3期随机双盲安慰剂对照多中心试验,方案按SPIRIT指南制定。
  • 纳入年龄≥18岁、实验室确诊COVID-19、有重症肺炎体征或症状且影像学确认重症肺炎的成人患者。
  • 受试者按2:1随机接受静脉瑞德西韦或安慰剂,疗程10天。
  • 主要终点为28天内临床改善时间,定义为六分类临床状态量表下降两类或存活出院。
  • 计划在观察到所需事件总数一半时进行一次疗效与无效性中期分析。

关键数值与推荐

  • 主要终点临床改善定义为六分类量表(1=出院;6=死亡)下降两类或存活出院,时间以天计,在28天截尾。
  • 随机比例为瑞德西韦:安慰剂=2:1。
  • 中期分析触发条件为观察到所需事件总数的一半。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards the end of 2019. Large-scale spread within China and internationally led the World Health Organization to declare a Public Health Emergency of International Concern on 30th January 2020. The clinical manifestations of COVID-19 virus infection include asymptomatic infection, mild upper respiratory symptoms, severe viral pneumonia with respiratory failure, and even death. There are no antivirals of proven clinical efficacy in coronavirus infections. Remdesivir (GS-5734), a nucleoside analogue, has inhibitory effects on animal and human highly pathogenic coronaviruses, including MERS-CoV and SARS-CoV, in in vitro and in vivo experiments. It is also inhibitory against the COVID-19 virus in vitro. The aim of this study is to assess the efficacy and safety of remdesivir in adult patients with severe COVID-19. METHODS: The protocol is prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. This is a phase 3, randomized, double-blind, placebo-controlled, multicentre trial. Adults (≥ 18 years) with laboratory-confirmed COVID-19 virus infection, severe pneumonia signs or symptoms, and radiologically confirmed severe pneumonia are randomly assigned in a 2:1 ratio to intravenously administered remdesivir or placebo for 10 days. The primary endpoint is time to clinical improvement (censored at day 28), defined as the time (in days) from randomization of study treatment (remdesivir or placebo) until a decline of two categories on a six-category ordinal scale of clinical status (1 = discharged; 6 = death) or live discharge from hospital. One interim analysis for efficacy and futility will be conducted once half of the total number of events required has been observed. DISCUSSION: This is the first randomized, placebo-controlled trial in COVID-19. Enrolment began in sites in Wuhan, Hubei Province, China on 6th February 2020. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04257656. Registered on 6 February 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wang Y, Zhou F, Zhang D, et al. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. Trials. 2020. PMID: 32448345. doi:10.1186/s13063-020-04352-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。